SUSTAINED RELEASE DELIVERY DEVICES
First Claim
1. A drug delivery device shaped and sized for injection comprising:
- a core including one or more drugs; and
a polymeric skin at least partially surrounding the core, the skin comprising a first one or more polymers.
1 Assignment
0 Petitions
Accused Products
Abstract
An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as “coatings,” “skins,” or “outer layers”). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles.
-
Citations
61 Claims
-
1. A drug delivery device shaped and sized for injection comprising:
-
a core including one or more drugs; and a polymeric skin at least partially surrounding the core, the skin comprising a first one or more polymers. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)
-
-
50. A drug delivery device comprising:
-
a drug core, preferably comprising a glucocorticoid, such as fluocinolone acetonide; a polymer tube, preferably a tube impermeable to the passage of drug, such as a tube comprising polyimide; and an outer layer covering at least one end, preferably covering both ends of the device and a portion of the tube, wherein the outer layer is permeable to the passage of drug; wherein the device releases the drug at a rate of less than about 0.5, about 0.4, about 0.3, about 0.2, or even less than about 0.1 μ
g/day. - View Dependent Claims (51, 52, 53)
-
-
54. A method for treating an eye disease or disorder with fewer side effects, comprising administering a drug to an eye of a patient in need thereof daily for a period of at least 3 months, wherein said drug is administered at a release rate of less than or equal to 0.4 μ
- g/day to treat said disease or disorder without causing a significant increase in IOP in a substantial percentage of treated patients.
- View Dependent Claims (55, 56, 57, 58, 59, 60)
-
61. A method for decreasing excess foveal thickness in a patient in need thereof, comprising administering a drug to an eye of said patient for a period of at least 3 months, wherein said drug is administered at a release rate of less than or equal to 0.4 μ
- g/day to decrease excess foveal thickness.
Specification